CME/CE
Clinical Evidence for Anti-CD38–Based Frontline Regimens in Transplant-Ineligible Patients With Multiple Myeloma
5:15
Faculty: Saad Z. Usmani, MD, MBA
This online educational activity reviews the clinical evidence supporting anti-CD38 monoclonal antibody–based combinations as foundational frontline therapy for patients with newly diagnosed multiple myeloma. Faculty examine pivotal clinical trial data and current NCCN Guidelines across transplant-eligible and transplant-ineligible populations, highlighting the…